Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
Authors:
Open Access
- 2 July 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 65, 104009
Abstract
No abstract availableKeywords
Funding Information
- Roche
- Sanofi Genzyme
- Biogen
- Cilag
- Teva Pharmaceutical Industries
- Austrian Science Fund (DOC 33-B27)
- European Committee for Treatment and Research in Multiple Sclerosis
- Novartis
- Sandoz
- GlaxoSmithKline
- Merck
- Bayer
- UCB
This publication has 19 references indexed in Scilit:
- COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster doseJournal of the Neurological Sciences, 2022
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisNeurology, 2021
- Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary ReportmedRxiv, 2021
- Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapiesEBioMedicine, 2021
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialThe Lancet, 2021
- Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical EvaluationJournal of Clinical Microbiology, 2021
- Effect of SARS-CoV-2 mRNA Vaccination in MS Patients Treated With Disease Modifying TherapiesSSRN Electronic Journal, 2021
- Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesTherapeutic Advances in Neurological Disorders, 2021
- Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidatesEmerging Microbes & Infections, 2021
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018